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Abstract
The role of catheter ablation in patients with atrial fibrillation (AF) in enhancing long-term outcomes
remains unknown. This meta-analysis aimed to assess the impact of catheter ablation on stroke, all-cause
mortality, hospitalization due to heart failure, and major bleeding events in patients with atrial fibrillation.
This meta-analysis was conducted in compliance with the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines. The data search was carried out by two authors independently
using online databases including PubMed, EMBASE, and Cochrane library. The primary outcome was a
stroke. The secondary outcomes were all-cause mortality, hospitalization for heart failure, and major
bleeding events. Total, 10 articles were included in the current meta-analysis encompassing 275392 patients
(33291 in the ablation group and 244974 in the non-ablation group). Among all included studies, one study
was a randomized control trial, while the remaining other were retrospective cohorts. The current metaanalysis showed that catheter-based AF ablation reduced the risk of stroke (hazard ratio {HR}: 0.61, 95% CI:
0.49-0.77), all-cause mortality (HR: 0.60, 95% CI: 0.51-0.71), and hospitalization for heart failure (HR: 0.57,
95% CI: 0.43-0.76). No significant differences were reported in terms of major bleeding events between
patients who received catheter-based AF ablation and patients who did not receive catheter-based AF
ablation (HR: 0.96, 95% CI: 0.80-1.14). In the current meta-analysis, catheter-based AF ablation was
associated with decreased risk of all-cause mortality, stroke, and hospitalization due to heart failure.
However, no significant difference was reported in terms of major bleeding events.

Categories: Cardiac/Thoracic/Vascular Surgery, Cardiology, Internal Medicine
Keywords: all-cause mortality, stroke, meta-analysis, atrial fibrillation, catheter ablation

Introduction And Background
Atrial fibrillation (AF) affects 3 to 5 million people in the United States and its prevalence and incidence have
been increasing every year [1]. Many patients who develop atrial fibrillation have certain comorbidities like
structural heart disease, hypertension, and diabetes [2]. Thus, these patients experience a significant risk of
cardiovascular events like heart failure and stroke [3].
Compared to just controlling the ventricular rate, sinus rhythm maintenance (rhythm control), which
reflects the normal heart rhythm, may be thought of as the most natural method (rate control) [4]. However,
rate control has been shown in major clinical trials to be non-inferior to rhythm control with antiarrhythmic
medications (AADs) in terms of preventing death, stroke, and heart failure [5]. The adverse effects and
proarrhythmic properties of anti-arrhythmic drugs along with their relatively modest efficacy in preserving
sinus rhythm, most certainly account for this [6]. Catheter ablation for atrial fibrillation has grown into an
important and effective option for many patients since its initial description in the late 1990s [7]. Several
clinical trials have shown that atrial fibrillation ablation maintains sinus rhythm more efficiently as
compared to anti-arrhythmic drugs as a second-line and possibly a first-line strategy [8-9]. This improved
sinus rhythm is linked with enhanced symptoms [10].
These trials have been debated widely but are not powered enough to show a possible effect on the outcomes
like all-cause mortality, hospitalization related to cardiovascular events, and stroke in patients undergoing
atrial fibrillation catheter ablation [11] or affected by the crossover between the study groups [12]. On the
other hand, findings from retrospective studies have shown the benefits of atrial fibrillation catheter
ablation in terms of clinical endpoint reductions.
There is a paucity of data related to the impact of catheter ablation on outcomes like mortality and stroke.
To fill this knowledge gap, this meta-analysis was performed to determine the effectiveness of catheterbased AF ablation by evaluating the impacts of catheter ablation on stroke, all-cause mortality,
hospitalization due to heart failure, and major bleeding events in patients with atrial fibrillation.
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Review
Methods
This meta-analysis was conducted in compliance with the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines.
Search Strategy
The data search was carried out by two authors independently using online databases including PubMed,
EMBASE and Cochrane library. The electronic search was carried out by combining the following key terms
and Medical Subject Headings (MeSH) terms: “atrial fibrillation”, “Catheter ablation”, “Hospitalization”,
“death”, and “stroke”. A reference list of all relevant studies was reviewed as well. All references were
downloaded into EndNote Version X9 (Thompson ISI ResearchSoft, Philadelphia, Pennsylvania). Duplicates
were removed manually and electronically.
Study Selection
Two investigators reviewed the title and abstract of studies independently to determine whether they are
eligible for full-text review based on the eligibility criteria. Title and abstract screening were followed by a
full-text review of relevant articles. Studies included in the current meta-analysis only if they fulfill the
following inclusion criteria (a) compared at least one of the three clinical outcomes (stroke, all-cause
mortality, and hospitalization for heart failure), (b) Compared catheter ablation with non-ablated atrial
fibrillation patients, (c) follow-up of at least one year, (d) include studies recruited patients exclusively with
normal left-ventricular ejection fraction (LVEF) of more than or equal to 40%. The inclusion criteria were not
limited to sample size and year of publication. Studies were excluded if they were published in a language
other than English. The discrepancy between the two authors was resolved via consensus or discussion with
a third author.
Quality Assessment
Risk of bias assessment of randomized control trial (RCT) was done using the Cochrane bias risk assessment
tool, while Newcastle‐Ottawa Scale was used for observational studies.
Data Extraction
Data were extracted by two authors independently using a structured data collection form. Data collected
included author name, year of publication, sample size, intervention, and follow-up time. The discrepancy
between the two authors was resolved via consensus or discussion with a third author.
Outcome Measures
The primary outcome was a stroke. The secondary outcomes were all-cause mortality, hospitalization for
heart failure, and major bleeding events. The definitions of the endpoints were taken as reported in the
included studies.
Statistical Analysis
Statistical analysis was performed using RevMan version 5.4.0 (The Nordic Cochrane Centre, The Cochrane
Collaboration, Copenhagen) and R version 4.1.2 (R Foundation for Statistical Computing, Vienna, Austria).
Estimates were pooled using a generic invariance-weighted random or fixed effect model. Outcomes were
computed as hazard ratio (HR) with a 95% confidence interval (CI). A p-value of 0.05 was set as significant. A
Forest plot was drawn for each outcome representing an individual estimate of each study and pooled
estimates. Heterogeneity was assessed utilizing Cochran's Q statistic and I-square. For significant
heterogeneity, a p-value<0.1 was considered significant. Heterogeneity was considered low (I2<25%),
moderate (25-50%) and high (>50%). For publication bias, the Egger test was used. P-value<0.05 was
considered significant for the publication bias. To identify the reasons for heterogeneity, meta-regression
was also performed to identify the potential association of moderator variables with the primary endpoint
(stroke) by taking the age of patients, gender, follow-up time, the prevalence of diabetes mellitus,
hypertension, and prevalence of heart failure as moderator variables. A P-value less than 0.05 was
considered significant.

Results
Figure 1 shows the PRISMA flowchart for the selection of studies. Overall, online searching yielded 1425
studies, of which 310 citations were removed as duplicates. Of the remaining 1115 articles, 1054 studies were
excluded after the title and abstract screening. The full text of 61 articles was reviewed for eligibility
criteria. Out of 61 articles, 10 articles fulfilled the eligibility criteria and were included in the current meta-
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analysis encompassing 275392 patients (33291 in the ablation group and 244974 in the non-ablation group).

FIGURE 1: PRISMA flowchart of selection of studies

Table 1 shows the characteristics of all included studies. Among all included studies, one study was a
randomized control trial, while the remaining studies were retrospective observational studies. The followup period of included studies ranged from 1 year to 4.5 years. In most of the studies, the majority of the
participants were males.

2022 Shaik et al. Cureus 14(9): e29202. DOI 10.7759/cureus.29202

3 of 9

First author

Year

Study type

Population

Retrospective

Patients with AF without prior stroke

cohort

or heart failure

Groups

Ablation
Chang et al.
[13]

2014

Non-

Ablation
2022

Retrospective
cohort

Non-

[15]

Retrospective
cohort

Ablation
Joza et al. [16]

2018

Retrospective
cohort

Ablation
al. [17]

2018

Retrospective
cohort

ablation
Ablation
Packer et al.
[12]

2019

RCT

Ablation
[18]

2012

Retrospective

Patients with a clinical diagnosis of

cohort

AF

Non-

Ablation
[19]

2016

Retrospective
cohort

Ablation
[20]

2018

Retrospective
cohort

Ablation
Yang et al. [21]

2020

Retrospective
cohort

ablation

14068
(55.1)

59.97

1892

(10.20)

(75.8)

59.55

1879

(12.83)

(76.2)

67.6

758

(7.6)

(61.1)

68.2

1481

(7.6)

(61.0)

63.7

7881

(11.1)

(65.5)

63.7

112482

(11.9)

(65.5)
695
(62.7)

NA
690
(63.0)
488
(60.9)

PSM

801

-

969

-

501
(62.6)
613
(63.3)

PSM

3772

-

4169

-

2369
(63.7)
3013
(72.3)

PSM

4169

-

9185

18770

(58.2)

(10.37)

-

3.5 Years

259

71

801

Patients with a diagnosis of AF
Non-

(59.3)

67 (7.41)

3.5 Years
ablation

6719

(12.69)

1096

Patients with a diagnosis of AF
Non-

66.98

68 (7.41)

4 Years
ablation

Srivatsa et al.

1108

Patients with a diagnosis of AF
Non-

(70.8)

PSW

171728

3 Years
ablation

Saliba et al.

12032

4 Years
Non-

599

(15.30)

PSM

2427

Patients with a diagnosis of AF
ablation

Reynolds et al.

1240

2.1 Years
Non-

51.91

PSM

2496

Patients with a diagnosis of AF

n(%)

PSM

2496

3.5 Years
Non-

Male

age (SD)

63 (9.62)

25518

Patients with a diagnosis of AF
ablation

Noseworthy et

445

4.4 Years
ablation

Mean

PSM

11324

Patients with a diagnosis of AF
Non-

Analysis

846

3 Years

Ablation
2016

time

Patients with a diagnosis of AF
ablation

Friberg et al.

Follow-up

Size

3.5 Years
ablation

Ding et al. [14]

Sample

2968
(71.2)

61

6696

(11.11)

(72.9)

62

13402

(12.59)

(71.4)

PSW

TABLE 1: Characteristics of included studies
AF: Atrial fibrillation; RCT: Randomized control trial; PSM: Propensity score matching; PSW: Propensity score weighting; SD: Standard deviation

Table 2 shows the quality assessment of all included retrospective studies. All included retrospective studies
have good quality. Table 3 shows the risk of bias assessment of the RCT included in the current meta-
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analysis. The risk of bias in that RCT is moderate.

Study Id

Selection

Comparibility

Outcome

Overall quality

Chang et al., 2014 [13]

4

1

3

Good

Ding et al., 2022 [14]

4

1

3

Good

Friberg et al., 2016 [15]

4

1

3

Good

Joza et al., 2018 [16]

4

1

3

Good

Noseworthy et al., 2018 [17]

4

2

2

Good

Reynolds et al., 2012 [18]

4

1

3

Good

Saliba et al., 2016 [19]

4

1

3

Good

Srivatsa et al., 2018 [20]

4

1

3

Good

Yang et al., 2020 [21]

4

1

3

Good

TABLE 2: Risk of bias assessment of retrospective studies

Study Id

Selection bias

Performance bias

Detection bias

Attrition bias

Reporting bias

Packer et al. [12]

Low

High

Low

Low

Low

TABLE 3: Risk of bias assessment of included RCT

Comparison of Outcomes Between Ablation and Non-Ablation Groups
A total of 10 studies compared the stroke between patients who received catheter ablation and patients who
did not receive ablation [12,13-21]. By random‐effect model meta‐analysis, catheter-based AF ablation
reduced the risk of stroke by 39% (HR: 0.61, 95% CI: 0.49-0.77) compared with patients treated with medical
therapy as shown in Figure 2. Heterogeneity was high as shown by its I-square value (I2=79%). No
publication bias was there for the stroke as the Egger test p-value was 0.36.

FIGURE 2: Forest plots comparing ablation vs. no ablation groups in
terms of prevention of stroke
Sources: References [12-21]

A total of eight studies assessed the all-cause mortality between the study groups [12-15,17,19-21]. The risk
of all-cause mortality was significantly lower in patients receiving catheter-based AF ablation compared to
patients treated with medical therapy (HR: 0.60, 95% CI: 0.51-0.71) as shown in Figure 3. Significant
heterogeneity was there among the study results (I-square=81%). However, no evidence of publication bias
was found in the outcome of interest (P-value of Egger test= 0.18).
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FIGURE 3: Forest plots comparing ablation vs. no ablation groups in
terms of risk of all-cause mortality
Sources: References [12-15,17,19-21]

Hospitalization for heart failure was assessed by four studies [13,18,20-21]. Catheter-based AF ablation
decreased the risk of hospitalization for heart failure in patients with atrial fibrillation as compared to its
counterparts (HR: 0.57, 95% CI: 0.43-0.76) as shown in Figure 4. Significant heterogeneity was there among
the study results (I-square=75%). However, no evidence of publication bias was found in the outcome of
interest (P-value of Egger test=0.33).

FIGURE 4: Forest plots comparing ablation vs. no ablation groups in
terms of hospitalization for heart failure
Sources: References [13,18,20-21]

The risk of major bleeding events was assessed by three studies in the current meta-analysis [14,16-17]. No
significant difference was found between the two study groups in terms of major bleeding events (HR: 0.96,
95% CI: 0.80-1.14) as shown in Figure 5. Significant heterogeneity was there among the study results (Isquare=47%).

FIGURE 5: Forest plots comparing ablation vs. no ablation groups in
terms of major bleeding events
Sources: References [14,16-17]

Meta-Regression
The evaluation of potential moderator variables via meta-regression showed that the benefits of catheter
ablation for the decrease in all-cause mortality were explained by the mean age of patients and history of
cerebrovascular disease and coronary artery disease. For studies with higher age of patients, catheter
ablation was associated with decreased benefit in the reduction of all-cause mortality (P-value=0.002), and
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hypertension (P-value=0.011)
Sensitivity Analysis
Table 4 shows the results of the sensitivity analysis. Findings of sensitivity analysis showed that by
analyzing retrospective studies including propensity score matching, findings in terms of stroke and allcause mortality were similar to overall findings. However, RCT conducted by Packer et al. [12] did not show
any significant impact of catheter ablation on stroke and all-cause mortality.

Study Type

Stroke

I2

All-cause mortality

I2

PSM [13-16, 18-20]

0.69 (0.60-0.79)

0%

0.59 (0.49-0.71)

46%

PSW [17, 21]

0.46 (0.32-0.65)

54%

0.56 (0.40-0.79)

52%

RCT [12]

0.42 (0.11-1.61)

-

0.85 (0.60-1.21)

-

TABLE 4: Results of sensitivity analysis
PSM: Propensity score matching; PSW: Propensity score weighting; RCT: Randomized control trial

Discussion
Even though atrial fibrillation catheter ablation has historically been used for improving quality of life and
symptom relief, whether it offers survival benefits has been a matter of controversy [22]. The current metaanalysis involving pooled analysis of RCT and retrospective cohort studies provides insights in this regard.
In patients with atrial fibrillation, catheter ablation can reduce the risk of all-cause mortality, stroke, and
hospitalization. Moreover, in terms of safety, no significant difference is there in major bleeding events
between patients who received catheter ablation and patients who received medical therapy.
Currently, atrial fibrillation catheter ablation is an option for rhythm control in patients with atrial
fibrillation who remain symptomatic on adequate rate control therapy. On the other hand, the demonstrated
improved efficacy and safety of catheter ablation in preserving sinus rhythm raises concerns about a
potential positive prognostic impact of the modern rhythm control method, either with catheter ablation
only or with a combination of catheter ablation and anti-arrhythmic drugs. RCT included in this metaanalysis [12] used intention to treat analysis and sensitivity analysis showed that no significant difference
was reported in stroke and all-cause mortality between catheter ablation and medical therapy. The results
of this trial were most likely to be affected by high treatment cross-over and lower mortality rate than
expected.
Various studies have shown that catheter ablation is better than medical treatment alone for the prevention
of recurrent atrial fibrillation, enhancement in quality of life, and reduction of morbidity [23]. Additionally,
it may appear reasonable that successful atrial fibrillation catheter ablation will result in a lower risk of
mortality and cerebrovascular-related events compared to antiarrhythmic medication therapy alone (a)
because people with atrial fibrillation had significantly lower survival rates than subjects without atrial
fibrillation [24] and increased risk of cardiac failure, (b) the burden of atrial fibrillation has been proven to be
associated with the risk of stroke [25], (c) ablation is more effective than anti-arrhythmic drugs to reduce the
atrial fibrillation burden and maintaining sinus rhythm [24]. Theoretically, successful atrial fibrillation
catheter ablation could decrease all-cause mortality by preventing thromboembolic outcomes,
cardiovascular mortality, and heart failure decompensation as shown by the Framingham Heart Study [26],
so simple by permitting patients to stop their anti-arrhythmic medications.
International guidelines currently encourage reserving atrial fibrillation catheter ablation for patients who
have experienced at least one anti-arrhythmic medication therapy failure, while it may be taken into
consideration in some patients with early forms of atrial fibrillation or heart failure with low ejection
fraction [27-28]. In several countries, health care structures are such that often a delay is observed between
the diagnosis of atrial fibrillation and specialist review and subsequent referral for consideration of atrial
fibrillation [14]. As a result, the adoption of atrial fibrillation ablation is uncommon [14]. However,
increasing evidence shows that atrial fibrillation ablation needs to be considered early [29]. Moreover, it is
crucial to emphasize the significance of preserving sinus rhythm [30]. The effectiveness of catheter ablation
is decreased with delays in treatment [31]. In order to achieve this goal, methodical advancements are
required to make it easier to deliver early atrial ablation to patients who are qualified and may benefit from
such treatment. This facilitation supports the need for patient care pathways to be more integrated,
including for patients with atrial fibrillation and other chronic cardiac illnesses [32].
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Limitations
One of the main limitations of this meta-analysis is linked to its methodology and the heterogeneity
between studies. The pooled analysis of all-cause mortality, stroke, and hospitalization was graded for
heterogeneity using the I-square test. Considering the methodological variations between observational
studies, this was anticipated from the start. Besides this, the majority of the studies included in the current
meta-analysis are retrospective in nature that needs to be interpreted cautiously because of their
observational nature. Although multivariable analysis and matching using propensity analysis can control
confounding variables, residual confounding attributed to unmeasured factors remains a concern.

Conclusions
In the current meta-analysis, catheter-based AF ablation was associated with decreased risk of all-cause
mortality, stroke, and hospitalization due to heart failure. However, no significant difference was reported
in terms of major bleeding events. Only observational studies have shown a decrease in the risk of stroke. To
determine whether ablation can improve survival in populations and reduce stroke, additional well-powered
randomized control trials are required.
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